ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERYFebruary 14, 2025By Adare Pharmaceuticals Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin…
This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While these powerful weight loss drugs are effective, a significant portion of the lost weight is…
According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience a significantly lower risk of fractures compared to those who undergo sleeve gastrectomy. Researchers utilized electronic health record data and…
Are you wanting to save some money? Discouraged by the high price of the GLP-1 drugs from the big pharmaceutical companies and the compounding pharmacies? Here is an overview of what to expect in creating your own personal drug company.…
Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102, Issue 13 This article explores the significant environmental challenges associated with the rapidly increasing production of…
Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038 Epub 2024 Aug 10. PMID: 39127792; PMCID: PMC11931505. Published 10 August 2024 This review article explores the…
This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic eating), “hungry gut” (abnormal satiety), and “slow burn” (decreased…
This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body…
The common belief is that as GLP-1s become more popular, that will stimulate competition in generics and new drug development. This is all good, right? However, this has not always been true. This news article provides a detailed account of…
Several companies and research groups are actively exploring implantable drug delivery systems for GLP-1 receptor agonists (GLP-1 RAs), aiming to improve patient adherence, convenience, and therapeutic outcomes. Here’s a summary of key players and motivations: Getting drugs into a human…